160 related articles for article (PubMed ID: 26985059)
1. The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST.
Pinker K; Riedl CC; Ong L; Jochelson M; Ulaner GA; McArthur H; Dickler M; Gönen M; Weber WA
J Nucl Med; 2016 Jul; 57(7):1102-4. PubMed ID: 26985059
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
[TBL] [Abstract][Full Text] [Related]
3. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
4. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
[TBL] [Abstract][Full Text] [Related]
5. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
6. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
7. Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing
Vogsen M; Harbo F; Jakobsen NM; Nissen HJ; Dahlsgaard-Wallenius SE; Gerke O; Jensen JD; Asmussen JT; Jylling AMB; Braad PE; Vach W; Ewertz M; Hildebrandt MG
J Nucl Med; 2023 Mar; 64(3):355-361. PubMed ID: 36207136
[TBL] [Abstract][Full Text] [Related]
8. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of early interim
Su TP; Huang JS; Chang PH; Lui KW; Hsieh JC; Ng SH; Chan SC
BMC Cancer; 2021 Aug; 21(1):908. PubMed ID: 34376155
[TBL] [Abstract][Full Text] [Related]
10.
Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
[TBL] [Abstract][Full Text] [Related]
11.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.
Tőkés T; Kajáry K; Szentmártoni G; Lengyel Z; Györke T; Torgyík L; Somlai K; Tőkés AM; Kulka J; Dank M
Breast Cancer; 2017 Jan; 24(1):137-146. PubMed ID: 26979062
[TBL] [Abstract][Full Text] [Related]
14. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST - multicenter study in Japan.
Kitajima K; Nakatani K; Yamaguchi K; Nakajo M; Tani A; Ishibashi M; Hosoya K; Morita T; Kinoshita T; Kaida H; Miyoshi Y
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1661-1671. PubMed ID: 29754160
[TBL] [Abstract][Full Text] [Related]
15. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S
Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
18. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
19. Clinical Value of
Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
[TBL] [Abstract][Full Text] [Related]
20. Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
Michl M; Lehner S; Paprottka PM; Ilhan H; Bartenstein P; Heinemann V; Boeck S; Albert NL; Fendler WP
J Nucl Med; 2016 Mar; 57(3):355-60. PubMed ID: 26609176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
